HomeATYR • NASDAQ
add
aTyr Pharma Inc
$3.03
Makalipas ang Oras ng Trabaho:(1.98%)+0.060
$3.09
Sarado: Nob 22, 5:03:35 PM GMT-5 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$2.98
Sakop ng araw
$2.95 - $3.19
Sakop ng taon
$1.42 - $3.19
Market cap
254.35M USD
Average na Volume
1.28M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 3.34M | 25.93% |
Net na kita | -17.26M | -52.20% |
Net profit margin | — | — |
Kita sa bawat share | -0.23 | -15.00% |
EBITDA | -17.96M | -44.42% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 65.99M | -35.39% |
Kabuuang asset | 91.62M | -26.75% |
Kabuuang sagutin | 26.48M | -1.45% |
Kabuuang equity | 65.14M | — |
Natitirang share | 83.94M | — |
Presyo para makapag-book | 3.47 | — |
Return on assets | -45.92% | — |
Return on capital | -52.14% | — |
Cash Flow
Net change in cash
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -17.26M | -52.20% |
Cash mula sa mga operasyon | -13.16M | -37.65% |
Cash mula sa pag-invest | 17.95M | 309.45% |
Cash mula sa financing | -105.00K | -103.91% |
Net change in cash | 4.68M | 287.77% |
Malayang cash flow | -6.49M | -12.66% |
Tungkol
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Itinatag
Ene 1, 2005
Website
Mga Empleyado
58
